Premium
BDNF Val 66 Met genotype is associated with drug‐seeking phenotypes in heroin‐dependent individuals: a pilot study
Author(s) -
Greenwald Mark K.,
Steinmiller Caren L.,
Śliwerska Elzbieta,
Lundahl Leslie,
Burmeister Margit
Publication year - 2013
Publication title -
addiction biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 78
eISSN - 1369-1600
pISSN - 1355-6215
DOI - 10.1111/j.1369-1600.2011.00431.x
Subject(s) - heroin , genotype , nicotine , brain derived neurotrophic factor , psychology , addiction , drug , allele , clinical psychology , allele frequency , neurotrophic factors , oncology , psychiatry , medicine , pharmacology , genetics , biology , gene , receptor
Brain‐derived neurotrophic factor (BDNF) Val 66 Met genotype has been associated with neurobehavioral deficits. To examine its relevance for addiction, we examined BDNF genotype differences in drug‐seeking behavior. Heroin‐dependent volunteers ( n = 128) completed an interview that assessed past‐month naturalistic drug‐seeking/use behaviors. In African Americans ( n = 74), the Met allele was uncommon (carrier frequency 6.8%); thus, analyses focused on European Americans ( n = 54), in whom the Met allele was common (carrier frequency 37.0%). In their natural setting, Met carriers ( n = 20) reported more time‐ and cost‐intensive heroin‐seeking and more cigarette use than Val homozygotes ( n = 34). BDNF Val 66 Met genotype predicted 18.4% of variance in ‘weekly heroin investment’ (purchasing time × amount × frequency). These data suggest that the BDNF Met allele may confer a ‘preferred drug‐invested’ phenotype, resistant to moderating effects of higher drug prices and non‐drug reinforcement. These preliminary hypothesis‐generating findings require replication, but are consistent with pre‐clinical data that demonstrate neurotrophic influence in drug reinforcement. Whether this genotype is relevant to other abused substances besides opioids or nicotine, or treatment response, remains to be determined.